Jefferies Group LLC Bellus Health Inc. Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$5.56 - $7.99 $1.8 Million - $2.59 Million	-324,476 Closed	0 $0
Q4 2021 Sep 21, 2023	BUY	$5.26 - $8.3 $1.08 Million - $1.7 Million	204,679 Added 170.85%	324,476 $2.61 Million
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $1.08 Million - $1.7 Million	204,679 Added 170.85%	324,476 $2.61 Million
Q3 2021 Sep 21, 2023	SELL	$2.7 - $6.64 $41,293 - $101,552	-15,294 Reduced 11.32%	119,797 $735,000
Q3 2021 Nov 15, 2021	BUY	$2.7 - $6.64 $323,451 - $795,452	119,797 New	119,797 $736,000
Q1 2021 May 14, 2021	SELL	$3.03 - $4.58 $409,325 - $618,716	-135,091 Closed	0 $0
Q4 2020 Sep 21, 2023	BUY	$2.27 - $3.3 $306,656 - $445,800	135,091 New	135,091 $413,000
Q4 2020 Feb 16, 2021	BUY	$2.27 - $3.3 $306,656 - $445,800	135,091 New	135,091 $413,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.